

## EMWA Newsblast - January 2020



### Webinar News

#### Webinar Programme

The Webinar Team wishes you a prosperous 2020! And what better way to begin the new year could there be than a great webinar!!!

We invite you to join us on the 9th of January 2020 at 14:00-15:00 CET for "Great topic – shame about the slides!" by John Dixon

Brief summary: We've all listened to experts delivering presentations on interesting and relevant topics. However, sometimes a slide appears that is impossible to read in 30 seconds because it's too busy, text is too small or contrast makes text difficult to see. And what about slides with multiple fonts, font sizes and colours; inconsistent line and paragraph spacing; poorly aligned text and images; arrows piercing text boxes? We are left thinking: 'Great topic, but it's a shame the slides were poor'.

As medical communication specialists, whether designing slides for someone else or for our own use, we all want to create easily read and professional-looking slides. Do join us for a discussion about slides. We'll look at some awful slides, consider some basic principles and admire some nice slides, but this is not a PowerPoint workshop!

Click [here](#) to register.

Then, on Thursday, February 6th at 14:00 CET we'll have: "How to ensure that your LinkedIn profile dovetails with your CV and effectively SELLS you" by Alistair Morris from CV and Interview Advisors. Please note that this will be a private company webinar.

### Predatory Journals News

Another step towards [defining predatory journals](#). A new comment article in Nature, headed up by lead-author Agnes Grudniewicz, unveils a new consensus-formed definition of predatory publishing, and provides some suggestions of steps to take in the future to tackle the problems developing from the phenomena.

The group of 43 participants, consisting of members of industry organisations, society and commercial publishers, research institutes, libraries, policymakers and other key academic roles, provided answers to 28 questions, and engaged in 12 hours of discussion to develop the documents, followed by 2 further rounds of feedback and revision.

The definition put forward by the group is as follows:

"Predatory journals and publishers are entities that prioritize self-interest at the expense of scholarship and are characterized by false or misleading information, deviation from best editorial and publication practices, a lack of transparency, and/or the use of aggressive and indiscriminate solicitation practices."

### Ambassador's Programme

#### Joint Position Statement on Predatory Journals

The American Medical Writers Association (AMWA), the European Medical Writers Association (EMWA) and the International Society for Medical Publication Professionals (ISMPP) recognize the challenges to scientific publishing being posed by predatory journals and their publishers, which employ practices undermining the quality, integrity and reliability of published scientific research. The joint position statement complements several other sets of guidelines that have helped define the characteristics of a predatory journal.

By joining with AMWA and ISMPP in both developing and publicizing the Joint Position Statement on predatory journals, EMWA is providing a valuable service to publication professionals around the world by enabling them to more easily read, understand, and apply the principles of this JPS.

In order to raise awareness among non-English speakers about the responsibilities of medical writers and publication professionals concerning this significant issue, EMWA has initiated the translation of this statement into European languages.

### JPS Translation

We are proud to announce the posting Romanian translation of the JPS by Georgiana Orbeanu and Carmen Schmechel.

To read the statement, please click [here](#)

We are currently looking for translators. If you would like to volunteer please contact Abe Shevack ([aspscientist@gmail.com](mailto:aspscientist@gmail.com)) or the EMWA Head Office ([info@emwa.org](mailto:info@emwa.org)).

### Regulatory News

- EMA has started review of meningioma risk with cyproterone medicines
- Review of Xeljanz (tofacitinib) - CHMP Opinion (to be used with caution in patients at high risk of blood clots)
- Review of Lemtrada (alemtuzumab) - CHMP Opinion (restriction of its use due to reports of rare but serious side effects)
- Pharmacovigilance 2030 published
- EMA guidance on good PV practices in pregnant and breastfeeding women released
- 4-year overview of pharmacovigilance activities in the EU shows robust and effective medicines safety system
- EMA communication: Interactive timeline describing the journey of a medicines for human use authorised through EMA
- FDA guidance on adaptive trial design released
- FDA's statement on the agency's efforts to protect patients through post-market drug safety surveillance practices

To read more, please click [here](#)

### RPD News

- ICH and EC Updates
- FDA Guidance on Adaptive Design Studies
- Certificates of Confidentiality
- NIH Data Management and Sharing Activities Related to Public Access and Open Science – Office of Science Policy
- International Committee of Medical Journal Editors Updated Guidance

To read more, please click [here](#)

### Member Alert

We have been made aware of a scam email requesting payment for unpaid membership. Please **do not** respond with any personal information as the email is not from EMWA.



Registered Office: Chester House, 68 Chestergate, Macclesfield, Cheshire SK11 6DY, United Kingdom  
Tel: +44(0)1625 664534 E-mail: [info@emwa.org](mailto:info@emwa.org)  
A Private Limited Company registered in England and Wales No: 03653609

Confidentiality Note: Please note that this e-mail and any files transmitted with it are intended for the use of the addressee only and may contain confidential and/or privileged information. If the reader of this e-mail is not the intended recipient, or the employee or agent responsible for delivering it to the intended recipient, you are hereby notified that reading this e-mail is strictly prohibited. If you have received this e-mail in error, please immediately return it to the sender and delete it from your system. This e-mail, and any attachments, has been checked by us for computer viruses. Although none have been detected we cannot guarantee that it is completely free from such problems and we do not accept any liability for loss or damage that may be caused. We would therefore advise you to carry out your own virus checks before opening any attachments. A copy of the EMWA Privacy policy can be found [here](#)

Copyright © 2020. All rights reserved.

Want to change how you receive these emails?  
You can [update your preferences](#) or [unsubscribe from this list](#)